CAAS Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

CAAS Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-547,805	Closed	-$36.8M	–	680
2021 Q4	$34.2M	Buy	547,805 +304,400	+125%	+$17.9M	0.83%	21
2021 Q3	$14.4M	Buy	+243,405	New	+$16M	0.29%	78
2021 Q2	–	Sell	-99,572	Closed	-$6.49M	–	1053
2021 Q1	$6.29M	Buy	+99,572	New	+$6.2M	0.07%	308

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAAS Capital Management's BMY Position: Q1 2022 in Review

CAAS Capital Management sold out of Bristol-Myers Squibb (BMY) in Q1 2022, closing a stake of 547,805 shares — an estimated $36.8M sold.

CAAS Capital Management first reported a position in BMY in Q1 2021 and held it in 3 quarters. The position peaked at $34.2M in Q4 2021. 2,515 funds tracked by Wall St. Rank hold BMY as of Q1 2022.

CAAS Capital Management reported no remaining Bristol-Myers Squibb position as of Q1 2022 after selling out during the quarter.
CAAS Capital Management sold 547,805 Bristol-Myers Squibb shares in Q1 2022, an estimated $36.8M.
CAAS Capital Management first reported a position in Bristol-Myers Squibb in Q1 2021 and held it in 3 quarters.
CAAS Capital Management's Bristol-Myers Squibb position peaked at $34.2M in Q4 2021.
2,515 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.